Which nerve root is addressed by an L4/L5 subpedicular transforaminal epidural steroid injection (ESI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 8, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Research

A L4/5 subpedicular transforaminal epidural steroid injection primarily addresses the L5 nerve root. This is because the nerve root exits below the corresponding vertebral level, meaning the L5 nerve root exits through the L5/S1 neural foramen, but it also traverses the lateral recess at the L4/5 level. When performing a transforaminal approach at the L4/5 level, the medication is delivered into the epidural space near where the L5 nerve root begins its course through the lateral recess and foramen. The subpedicular technique specifically targets the superior aspect of the neuroforamen, just below the pedicle of L4, where the L5 nerve root is located. This approach allows the steroid medication to bathe the L5 nerve root as it courses through this region, reducing inflammation and providing pain relief for patients with L5 radiculopathy. The medication can also spread to affect adjacent levels to some degree, but the primary target is the L5 nerve root.

Key Points

  • The L5 nerve root is the primary target for a L4/5 subpedicular transforaminal epidural steroid injection 1
  • The subpedicular technique targets the superior aspect of the neuroforamen, just below the pedicle of L4, where the L5 nerve root is located
  • The medication can spread to affect adjacent levels, but the primary target is the L5 nerve root
  • Transforaminal epidural steroid injections have been shown to be effective in reducing pain and improving function in patients with lumbar radiculopathy 2, 3

Evidence Summary

The most recent and highest quality study on this topic is a prospective, randomized trial published in 2022 1. This study compared the effectiveness of the subpedicular and retrodiscal approaches for transforaminal epidural injections and found that both approaches were effective in reducing pain, but the retrodiscal approach showed a better contrast spreading pattern, especially in patients with severe central and foraminal spinal stenosis. Another study published in 2022 3 reviewed the efficacy and risks of epidural steroid injections, including transforaminal injections, and found that they can be an effective treatment for radicular pain.

Clinical Implications

In clinical practice, a L4/5 subpedicular transforaminal epidural steroid injection can be an effective treatment option for patients with L5 radiculopathy, especially those who have not responded to conservative treatments. The subpedicular technique allows for targeted delivery of steroid medication to the L5 nerve root, reducing inflammation and providing pain relief. However, it is essential to consider the individual patient's clinical presentation, pathology, anatomy, and unique risks and benefits of the technique when selecting an injection approach 3.

Related Questions

What is the significance of a 0.3 centimeter retrolisthesis of the first lumbar (L1) vertebra on the second lumbar (L2) vertebra?
What evidence supports lumbar transforaminal epidural steroid injections providing more than 80% relief for radiculopathy?
Do epidural steroid injections (e.g., methylprednisolone or triamcinolone) cause destruction of the intervertebral disc or surrounding spinal tissue?
Is a lumbar transforaminal epidural injection (64483) medically necessary for a patient with a history of chronic back pain, radiculopathy (M54.16), and previous response to injections, currently experiencing a pain level of 6/10 and limited daily activities due to pain, despite ongoing conservative treatments including physical therapy, home exercises, and medication with tizanidine (Zanaflex) and tylenol (acetaminophen)?
For a patient with a six‑week history of disc‑bulge radiculopathy refractory to activity modification, physical therapy, nonsteroidal anti‑inflammatory drugs (NSAIDs), and oral steroids, should I perform a lumbar transforaminal epidural steroid injection rather than a sacroiliac (SI) joint injection?
What are the effects and side effects of immediate-release versus slow-release melatonin (Melatonin), particularly regarding their impact on anxiety and low mood?
What is the risk of Stevens-Johnson Syndrome (SJS) with Febuxostat (Uloric) versus Allopurinol (Zyloprim), and when should treatment be initiated or avoided?
Would a patient with Hallucinogen Persisting Perception Disorder (HPPD) experiencing anxiety the day after taking melatonin (N-acetyl-5-methoxytryptamine) benefit from a slow-release or immediate-release formulation?
Are doxepin, zolpidem (Ambien), and eszopiclone (Lunesta) associated with addiction?
When to recheck lipid profile after a change in statin (HMG-CoA reductase inhibitor) dosage?
Does right hemiparesis (right-sided weakness) indicate right-sided symptoms or right cerebral hemisphere involvement?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.